News & Updates

Welldoc Announces Providence Health & Services’ Implementation of BlueStar® Digital Therapeutic in a Pilot Program for Individuals with Type 2 Diabetes

April 3, 2018

Colum­bia, MD, April 3, 2018​ – Today, Well­doc ® announced a pilot pro­gram in the Prov­i­dence Health & Ser­vices Oregon/SW Wash­ing­ton Region to exam­ine the use of Welldoc’s BlueS­tar®, an FDA-cleared, proven dig­i­tal ther­a­peu­tic for indi­vid­u­als with type 2 dia­betes. The Prov­i­dence Health & Ser­vices pilot pro­gram will include indi­vid­u­als liv­ing with type 2 dia­betes and will eval­u­ate the impact of a dig­i­tal therapeutic—when used in con­junc­tion with the sup­port of a ded­i­cat­ed Dia­betes Educator—on user engage­ment, reten­tion, sat­is­fac­tion and clin­i­cal out­comes.

We’re pleased to announce this pilot pro­gram with Prov­i­dence Health & Ser­vices,” said Well­doc Pres­i­dent and CEO Kevin McRaith. “We expect great out­comes from this ini­tial engage­ment and look for­ward to expand­ing our part­ner­ship to scale to meet the needs of all Prov­i­dence patients liv­ing with type 2 dia­betes.”

BlueS­tar pro­vides real-time and time­ly indi­vid­u­al­ized coach­ing and sup­port, as well as dia­betes edu­ca­tion­al tools that are action­able and per­son­al for indi­vid­u­als liv­ing with type 2 dia­betes. Clin­i­cal evi­dence shows a 1.7 to 2.0-point mean A1C reduc­tion for adults liv­ing with type 2 dia­betes who used BlueS­tar. BlueS­tar har­ness­es evi­dence-based dia­betes man­age­ment, behav­ior man­age­ment, and user expe­ri­ence to engage and pro­vide indi­vid­u­al­ized guid­ance when need­ed to peo­ple with type 2 dia­betes. It pro­vides this with­in a scal­able self-man­age­ment plat­form built on adap­tive in-app coach­ing and action­able patient-gen­er­at­ed health data. This plat­form is designed to con­nect adults liv­ing with type 2 dia­betes, their health care team mem­bers, and pay­ers through enhanced com­mu­ni­ca­tion and sup­port – result­ing in proven clin­i­cal out­comes and cost sav­ings.

About BlueS­tar®

BlueS­tar®, pow­ered by Well­doc®, is an FDA-cleared, proven dig­i­tal ther­a­peu­tic that is an in-app coach engag­ing peo­ple with type 2 dia­betes. It deliv­ers per­son­al­ized, real-time feed­back, as well as dia­betes edu­ca­tion­al tools that are action­able and indi­vid­u­al­ized. Specif­i­cal­ly, Well­doc has devel­oped more than 30 peer-reviewed pub­li­ca­tions and pre­sen­ta­tions on BlueS­tar, includ­ing two ran­dom­ized, con­trolled clin­i­cal tri­als. Our clin­i­cal evi­dence shows a 1.7 to 2.0-point mean A1C reduc­tion for adults liv­ing with type 2 dia­betes who used BlueS­tar. In Novem­ber 2017, the IQVIA Insti­tute for Human Data Sci­ence (for­mer­ly Quintiles/IMS) named BlueS­tar the “top app” in clin­i­cal dia­betes treat­ment. BlueS­tar deliv­ers an esti­mat­ed aver­age cost sav­ings of $254-$271 per user per month, proven clin­i­cal out­comes and a net pro­mot­er mem­ber sat­is­fac­tion score of 70. For more infor­ma­tion on BlueS­tar, vis­it: www2.bluestardiabetes.com.

This year, Sam­sung Elec­tron­ics Amer­i­ca, Inc. and Well­doc announced that Sam­sung Health users now have access to a new con­sumer ver­sion of Welldoc’s dig­i­tal plat­form known as the Dia­betes Well­ness Pro­gram (DWP). The DWP, which is inte­grat­ed with­in the Sam­sung Health ser­vice, is a 12-week health and well­ness pro­gram designed to help adults with type 2 dia­betes achieve a healthy lifestyle and to help man­age their con­di­tion. More infor­ma­tion on DWP is avail­able at: www.welldoc.com/diabeteswellness.

About Well­doc®

Well­doc® is a lead­ing dig­i­tal ther­a­peu­tic com­pa­ny rev­o­lu­tion­iz­ing chron­ic dis­ease man­age­ment to help trans­form lives. Our ground­break­ing tech­nol­o­gy is guid­ing indi­vid­u­als through the com­pli­cat­ed jour­ney of liv­ing with chron­ic dis­eases, with a goal of help­ing indi­vid­u­als self-man­age their con­di­tions to achieve sig­nif­i­cant clin­i­cal out­comes and cost sav­ings. We began our jour­ney by mas­ter­ing dia­betes man­age­ment solu­tions and are mov­ing rapid­ly into cre­at­ing addi­tion­al tools for man­ag­ing oth­er chron­ic dis­eases includ­ing hyper­ten­sion, chron­ic obstruc­tive pul­monary dis­ease (COPD) and con­ges­tive heart fail­ure (CHF). We are the first dig­i­tal health com­pa­ny based on a life sci­ence busi­ness mod­el with a foun­da­tion that is built on ran­dom­ized clin­i­cal tri­als that demon­strate sig­nif­i­cant clin­i­cal out­comes. We have tak­en an aggres­sive and inno­v­a­tive approach that uti­lizes sophis­ti­cat­ed log­ic, pre­cise algo­rithms, and arti­fi­cial intel­li­gence (AI), which inte­grates the most advanced mobile tech­nol­o­gy and behav­ioral insights. Well­doc part­ners with, col­lab­o­rates with, and is backed by top health­care com­pa­nies (includ­ing Mer­ck and John­son and John­son), lead­ing inno­va­tors, ded­i­cat­ed investors, and top mobile tech­nol­o­gy com­pa­nies (such as Sam­sung). For more infor­ma­tion, vis­it www.welldoc.com.